Vir Biotechnology (VIR) has entered into an exclusive licensing agreement with Norgine Pharma UK Limited, granting Norgine commercial rights for the combination of tobevibart and elebsiran for chronic hepatitis delta (CHD) treatment across Europe, Australia, and New Zealand. Under this agreement, Vir Biotechnology will receive an upfront payment of EUR 55 million and may receive up to EUR 495 million in additional clinical, regulatory, and sales milestone payments, along with royalties ranging from the mid-teens to high-twenties percent on net sales in the licensed regions.
Vir Biotechnology will maintain its commercialization rights for these treatments in the United States and other markets outside Greater China. Additionally, Norgine will contribute about 25% to the clinical development costs for the ongoing ECLIPSE program trials. This partnership is expected to extend Vir's financial resources into the fourth quarter of 2027 based on current plans.
Furthermore, Vir Biotechnology announced the completion of enrollment for the ECLIPSE 3 Phase 2b trial, comparing tobevibart and elebsiran with bulevirtide in bulevirtide-naive patients, aimed at supporting access and reimbursement in Europe. Previous data from the Phase 2 SOLSTICE trial showed promising results in hepatitis delta virus RNA reduction, with the combination treatment being well-tolerated and showing no significant adverse events.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.